摘要
目的对2005-2021年Web of science核心数据库新型免疫检查点抑制剂相关文献进行可视化分析,以探索新型免疫检查点抑制剂的研究趋势和发展方向。方法利用Web of science核心数据库进行检索,限定检索式为novel checkpoint inhibitor AND immunotherapy,检索2005年1月1日-2021年12月31日发表的有关新型免疫检查点抑制剂的相关文献,对相关文献发表的国家和地区期刊及文献中的关键词进行可视化分析。结果关于国家和地区的发文数量,美国、中国和意大利位列前3名。得克萨斯大学安德森癌症研究中心、哈佛大学医学院和美国国家癌症研究所是发文量前3名的机构。该领域内发表文献的期刊相对集中,多为肿瘤学和免疫学为主题的杂志。在关键词分析中可知,可关注以PD-1/PD-L1抑制剂与新型免疫检查点抑制剂(如:替瑞利尤单抗)的联合应用,同时也应该关注肿瘤免疫微环境中的免疫靶点:如CD73、4-1BB、CD8+T细胞、NK细胞。结论采用文献计量学分析方法分析新型免疫检查点抑制剂的相关文献,发现其研究进展和关注的热点,从而为免疫检查点抑制剂治疗的研究提供参考。
Objective To visually analyze the related literature of novel checkpoint inhibitors and immunotherapy in Web of science core database from 2005 to 2021 and to explore the development trend.Methods Web of science core database was used for retrieval,with the limited search formula of novel checkpoint inhibitors AND immunotherapy and the search time range was from January 1,2005 to December 31,2021.The published literatures on new immunosuppressive agents were visually analyzed on the national and regional journals and the key words in the literatures.Results As for the number of documents issued by countries and regions,USA,China and Italy ranked in the top three.The Anderson Cancer Research Center of the University of Texas,the Harvard Medical School and the National Cancer Institute of the United States are the top three institutions in terms of the number of papers.The journals that published literature in this field were relatively concentrated,and most of them were journals with the themes of oncology and immunology.According to the keyword analysis,we could focus on the combined application of PD-1/PD-L1 inhibitors and new immunocheckpoint inhibitors(such as tiragolumab),as well as the immune targets in the tumor immune microenvironment,such as CD73,4-1BB,CD8+T cells and NK cells.Conclusion The article adopts bibliometric analysis method to summarize the research progress and focus of novel checkpoint inhibitors and immunotherapy,so as to provide references for future research.
作者
阎金杉
李智
徐璐
李贺明
冮筱毓
赵明芳
Yan Jinshan;Li Zhi;Xu Lu;Li Heming;Gang Xiaoyu;Zhao Mingfang(Department of No.2 Oncology Medicine,the First Hospital of China Medical University,Shenyang 110001,China)
出处
《实用药物与临床》
CAS
2022年第12期1077-1082,共6页
Practical Pharmacy and Clinical Remedies
